<DOC>
	<DOCNO>NCT00036036</DOCNO>
	<brief_summary>The purpose study determine efficacy CP-461 give twice-daily orally locally advanced metastatic renal cell cancer evaluate safety profile CP-461 patient population .</brief_summary>
	<brief_title>Study CP-461 Patients With Advanced Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>1 . Measurable metastatic locally advanced disease . 2 . Histologically confirm renal cell cancer . 3 . No radiotherapy within 4 week prior enter study . No 1 prior systemic therapy advance disease . Prior adjuvant systemic therapy allow . Patients must fully recover acute effect prior therapy . 4 . Expected remain life span &gt; = three month . 5 . ECOG performance status 02 . 6 . &gt; = 18 year legal age . 7 . Male patient , nonpregnant nonlactating female patient either use adequate birth control , surgically sterile postmenopausal . 8 . Negative serum pregnancy test , fertile female . 9 . Willingness ability sign inform consent document . 1 . Uncontrolled symptomatic brain metastasis . 2 . Use investigational medication device within one month initiate study therapy . 3 . Absolute granulocyte count &lt; = 1500/mm3 ; Platelet count &lt; = 100,000/mm3 ; total serum bilirubin upper limit normal ; serum creatinine &gt; = 2.2 mg/dL ; AST/ALT &gt; 2.5 ULN . 4 . Any condition medication may interfere conduct study . 5 . Current active malignancy renal cell cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>renal</keyword>
	<keyword>renal cell cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
</DOC>